LENZ - LENZ Therapeutics, Inc.

QQQ $ 612.14 $ 1.56 (0.26 %)

DIA $ 470.45 $ 1.64 (0.35 %)

SPY $ 672.31 $ 2.95 (0.44 %)

TLT $ 89.45 $ -0.19 (-0.21 %)

GLD $ 367.77 $ 0.35 (0.1 %)

Previous Close

$ 22.97

Open

$ 22.31

Bid

$ 22.50 x 25

Ask

$ 24.00 x 200

Day's Range

$ 22.01 - $ 23.93

52 Week Range

$ 16.54 - $ 50.40

Volume

1,703,957

Average Volume

Market Cap

718.73M

Beta (5Y Monthly)

$ 1.68

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-05-2025	09-30-2025	10-Q
2	07-30-2025	06-30-2025	10-Q
3	05-07-2025	03-31-2025	10-Q
4	03-19-2025	12-31-2024	10-K
5	11-06-2024	09-30-2024	10-Q
6	08-14-2024	06-30-2024	10-Q
7	05-08-2024	03-31-2024	10-Q
8	02-27-2024	12-31-2023	10-K
9	11-13-2023	09-30-2023	10-Q
10	08-14-2023	06-30-2023	10-Q
11	05-11-2023	03-31-2023	10-Q
12	03-20-2023	12-31-2022	10-K
13	11-09-2022	09-30-2022	10-Q
14	08-11-2022	06-30-2022	10-Q
15	05-12-2022	03-31-2022	10-Q
16	03-21-2022	12-31-2021	10-K
17	11-10-2021	09-30-2021	10-Q
18	08-12-2021	06-30-2021	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

10 Health Care Stocks Whale Activity In To...
11/05/2025 17:35:20

LENZ Therapeutics Q3 EPS $(0.59) Beats $(0...
11/05/2025 13:06:47

LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0...

Earnings Scheduled For November 5, 2025
11/05/2025 11:12:12

Raymond James Reiterates Outperform on LEN...
10/20/2025 17:18:26

Raymond James analyst Gary Nachman reiterates LENZ Therapeutics (NASDAQ:LENZ) with a Outperform and raises the price target ...

Piper Sandler Maintains Overweight on LENZ...
10/10/2025 12:52:39

Piper Sandler analyst Biren Amin maintains LENZ Therapeutics (NASDAQ:LENZ) with a Overweight and raises the price target fro...

LENZ Therapeutics' VIZZ Commercially Avail...
09/30/2025 12:06:37

VIZZ sample distribution initiated nationwide to Eye Care ProfessionalsCommercial product shipments to be initiated in October ...

12 Health Care Stocks Moving In Monday's P...
08/11/2025 12:08:21

why-international-money-express-shares-are-trading-higher-by-around-54-here-are-20-stocks-moving-premarket

Why International Money Express Shares Are...
08/11/2025 09:22:11

Citigroup Maintains Buy on LENZ Therapeuti...
08/01/2025 19:53:01

Citigroup analyst Yigal Nochomovitz maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and raises the price target from $4...

HC Wainwright & Co. Maintains Buy on LENZ ...
08/01/2025 17:24:32

HC Wainwright & Co. analyst Matthew Caufield maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and raises the price t...

lenz-therapeutics-eye-drop-scores-first-fda-approval-for-age-related-blurred-vision-condition-impacting-128-million-people

LENZ Therapeutics' Eye Drop Scores First F...
08/01/2025 14:25:51

LENZ Therapeutics' VIZZ earns FDA approval as the first aceclidine-based eye drop to treat presbyopia, with U.S. launch exp...

Citigroup Maintains Buy on LENZ Therapeuti...
07/31/2025 23:07:57

Citigroup analyst Yigal Nochomovitz maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and raises the price target from $4...

Trading Halt: Halt status updated at 4:20:...
07/31/2025 20:20:09

LENZ Therapeutics Wins FDA Approval For VI...
07/31/2025 20:15:11

VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition imp...

Trading Halt: Halted at 4:01:07 p.m. ET - ...
07/31/2025 20:02:25

Raymond James Maintains Outperform on LENZ...
07/31/2025 14:31:18

Raymond James analyst Gary Nachman maintains LENZ Therapeutics (NASDAQ:LENZ) with a Outperform and raises the price target f...

LENZ Therapeutics Q2 EPS $(0.53) Beats $(0...
07/30/2025 12:11:48

LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0...

ENZ Therapeutics Says CORXEL Submits NDA F...
07/28/2025 12:06:47

LENZ Therapeutics, Inc. (NASDAQ:LENZ, "LENZ" or the "Company"))), a pre-commercial stage biopharmaceutical comp...

HC Wainwright & Co. Maintains Buy on LENZ ...
07/28/2025 10:15:16

HC Wainwright & Co. analyst Matthew Caufield maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and raises the price t...

LENZ Therapeutics And Laboratoires Théa An...
07/07/2025 12:05:50

LENZ Therapeutics, Inc. (NASDAQ:LENZ) and Laboratoires Théa ("Théa") announced an exclusive license and commercializati...